Literature DB >> 22472047

Comparative study of transplantation of hepatocytes at various differentiation stages into mice with lethal liver damage.

Ryo Kamimura1, Takamichi Ishii, Naoya Sasaki, Masatoshi Kajiwara, Takafumi Machimoto, Michiko Saito, Kenji Kohno, Hirofumi Suemori, Norio Nakatsuji, Iwao Ikai, Kentaro Yasuchika, Shinji Uemoto.   

Abstract

Hepatocyte transplantation utilizing induced pluripotent stem cells (iPSCs) or embryonic stem cells (ESCs) has been expected to provide an alternative to liver transplantation. However, it remains uncertain precisely which cell type is the best suited for cell transplantation. In particular, it is unclear whether mature hepatocytes, which have sufficient liver function, or immature hepatic progenitor cells, which have a higher proliferative capacity, will provide a better outcome. The main objective of this study was to investigate the therapeutic efficacy of the transplantation of hepatocytes at various differentiation stages. We utilized transgenic mice that expressed diphtheria toxin (DT) receptors under the control of an albumin enhancer/promoter. ESC-derived endodermal cells, fetal hepatocytes, and adult hepatocytes were transplanted into these mice with experimentally induced lethal acute liver injury caused by DT administration. The transplanted cells were marked by enhanced green fluorescent protein. We evaluated their effects on survival. At 35 days after transplantation, the survival rate of the adult hepatocyte-transplanted group (8/20, 40%) was significantly improved in comparison to that of the sham-operated group (2/25, 8%), the fetal hepatocyte-transplanted group (1/20, 5%), and the ESC-derived endodermal cell-transplanted group (0/21, 0%). The adult hepatocytes proliferated in the recipient livers and replaced a large part of their parenchyma. The transplantation of adult hepatocytes for acute liver failure significantly improved the survival rate in comparison to that of transplantation of immature cells, thus suggesting that ESCs and iPSCs should be differentiated into mature hepatocytes before cell transplantation for acute liver failure.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22472047     DOI: 10.3727/096368912X636957

Source DB:  PubMed          Journal:  Cell Transplant        ISSN: 0963-6897            Impact factor:   4.064


  4 in total

1.  New Tools in Experimental Cellular Therapy for the Treatment of Liver Diseases.

Authors:  Jennifer R Ferrer; Attasit Chokechanachaisakul; Jason A Wertheim
Journal:  Curr Transplant Rep       Date:  2015-06-01

2.  New directions for cell-based therapies in acute liver failure.

Authors:  Preeti Viswanathan; Sanjeev Gupta
Journal:  J Hepatol       Date:  2012-06-16       Impact factor: 25.083

3.  Cell-based therapy for acute and chronic liver failures: distinct diseases, different choices.

Authors:  Kai Sun; Xuqin Xie; Jing Xie; Shufan Jiao; Xiaojing Chen; Xue Zhao; Xin Wang; Lixin Wei
Journal:  Sci Rep       Date:  2014-09-29       Impact factor: 4.379

4.  Human fetal liver cells for regulated ex vivo erythropoietin gene therapy.

Authors:  Ebtisam El Filali; Suzanne Duijst; Johan K Hiralall; Nicolas Legrand; Thomas van Gulik; Ruurdtje Hoekstra; Jurgen Seppen
Journal:  Mol Ther Methods Clin Dev       Date:  2014-03-12       Impact factor: 6.698

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.